Personalizing medicine for cancer: the next decade.
An important outcome of the focus on the human genome in the past decade has been the understanding that cancer is largely a disease of aberrant cell signalling. The development of drugs that target the results of genetic defects in selected patients with cancer has led to some important treatment advances, but there remain major challenges to realizing the full potential of genomic medicine in oncology.
Borden
Ernest C
EC
Taussig Cancer Institute, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, Ohio 44195, USA. bordene@ccf.org
Raghavan
Derek
D
D000970:Antineoplastic Agents / Q000494:pharmacology*; D016503:Drug Delivery Systems; D015195:Drug Design; D015894:Genome, Human; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000235:genetics; D057285:Precision Medicine / Q000639:trends*; D017422:Sequence Analysis, DNA; D015398:Signal Transduction
D000970:Antineoplastic Agents